MariMedMRMD -1.24% Return-on-Tangible-Equity is -162.26% as of Mar. 2026. The stock has 5 warning signs investors should review. Among 895 Drug Manufacturers companies, MariMed ranks worse than 94.64% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MariMed's annualized net income for the quarter that ended in Mar. 2026 was $-15.1 Mil. MariMed's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $9.3 Mil. Therefore, MariMed's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -162.26%.
The historical rank and industry rank for MariMed's Return-on-Tangible-Equity or its related term are showing as below:
MRMD'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -244.84 Med: -36.45 Max: 39.1
Current: -86.02
During the past 13 years, MariMed's highest Return-on-Tangible-Equity was 39.10%. The lowest was -244.84%. And the median was -36.45%.
MRMD's Return-on-Tangible-Equity is ranked worse than 94.64% of 895
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs MRMD: -86.02
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
MariMed Return-on-Tangible-Equity Related Terms
MariMed Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for MariMed's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRMD vs RMTI, CPHI, TXMD: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MariMed Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MariMed's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where MariMed's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -162.26% mean?
MariMed (MRMD) has a Return-on-Tangible-Equity of -162.26% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MariMed and its competitors. According to the industry distribution chart, MariMed ranks #847 out of 895 companies in the Drug Manufacturers industry, placing it in the top 94.6%.
Is MariMed's Return-on-Tangible-Equity too high?
MariMed's current Return-on-Tangible-Equity is -162.26%. Based on the distribution chart, MariMed ranks #847 out of 895 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does MariMed's Return-on-Tangible-Equity compare to RMTI and CPHI?
According to the Drug Manufacturers industry distribution chart, MariMed ranks #847 out of 895 companies for Return-on-Tangible-Equity. This places MariMed in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 895 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MariMed and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MariMed's current Return-on-Tangible-Equity is -162.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 57.7% below its estimated fair value. The current Return-on-Tangible-Equity is -162.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MariMed (MRMD), the current Return-on-Tangible-Equity is -162.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRMD has been successfully added to your 